NACDS Statement on FDA’s Recommendation to Reschedule Hydrocodone

Published Online: Friday, October 25, 2013
Follow Pharmacy_Times:
PRESS RELEASE

Arlington, Va. - NACDS issued the following statement on October 24 regarding news that the Food and Drug Administration (FDA) is recommending the rescheduling of combination hydrocodone medications from Schedule III to Schedule II:

“Pharmacies have a zero tolerance for prescription drug abuse and a 100-percent commitment to patient care. This proposal is not the best avenue to address abuse, and would negatively impact access to needed medications for those who suffer from chronic pain. In the interest of patient care, we have worked with patient advocacy groups in opposition to this recommendation as we support and advance workable solutions.”

For more information, please see a recent column by NACDS President and CEO Steven C. Anderson, IOM, CAE, titled “Addressing Prescription Drug Abuse and Access Issues – Every Day.”
Related Articles
Twenty-two pharmacists and doctors were arrested in the Drug Enforcement Administration's “Operation Pilluted” aimed at curbing prescription drug abuse.
Chronic pain patients using prescription opioids in conjunction with medical marijuana are not at increased risk for substance abuse.
Tighter hydrocodone regulations meant to reduce opioid abuse are hindering pain patients’ access to the products.
Mylan Inc. has introduced 3 generic versions of existing drugs to the US market, including the first and only available intermediate dosages of transdermal fentanyl.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$